Bio News

Bio.News is a daily online news platform that delves into the exciting world of biotechnology and how it interacts with both U.S. and global policies. Our team of independent journalists from various parts of the globe covers this rapidly evolving industry, highlighting how different levels of government can either promote or hinder biotech advancements and investments. Additionally, we provide insights from leading scientists and biotech executives, discussing ways to propel the biorevolution forward.

International

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#3032130

United States

#1222918

Health/Biotechnology and Pharmaceuticals

#1067

Traffic sources

Monthly visitors

Articles

Alzheimer's Awareness Month: What to know

5 days ago | bio.news | Clary Estes

Over 7 million Americans live with Alzheimer’s disease, according to the Alzheimer’s Association. For June’s Alzheimer’s Awareness Month, Bio.News sat down with the Alzheimer’s Association to talk about the top four things to know about the disease. Many wonder what the difference is between Alzheimer’s and dementia. As the Alzheimer’s Association explains, dementia is an umbrella term for a particular group of symptoms, one cause of which is Alzheimer’s disease.
BIO 2025: What is the PRV program and why does it matter?

1 week ago | bio.news | Clary Estes

Established in 2012, the Pediatric Priority Review (PPRV) program offers a powerful incentive for companies to develop treatments for rare conditions affecting children. Even though the program was incredibly successful in helping spur drug development for some of the most challenging rare diseases, the program’s authorization expired in 2024. As such, patient advocates and drug developers who are working in the rare disease space have been calling for its reauthorization.
BIO 2025: 'Behind every data point there is a person'

1 week ago | bio.news | Clary Estes

The 2025 Biotechnology Innovation Organization (BIO) International Convention highlighted why we – the biotech industry – do what we do. In one word: patients. On Day 3, a panel, “Recognizing the Why Behind Our Medicines: Patient Connection as a Motivator for Impact,” featured patient advocates and biotech leaders examining the importance of putting patients front of mind in everything that they do.
BIO 2025: Rare disease patients can't wait

1 week ago | bio.news | Clary Estes

The rare disease patient community is the beating heart of the Biotechnology Innovation Organization’s (BIO) mission. Whether it is driving policy that supports innovation, improving coordination with regulatory bodies, or facilitating partnerships, BIO is committed to helping rare disease patients live longer, healthier lives. Rare disease has been a major theme at the 2025 BIO International Convention. As many of the discussions from the week have shown, rare disease patients can’t wait.
BIO 2025: Let's talk about sex (differences!) – specifically, women's health

1 week ago | bio.news | Samantha Sault

On Day 1 of the 2025 Biotechnology Innovation Organization (BIO) International Convention, a clear challenge was issued to the biotech industry: redefine how we understand, research, and invest in women’s health. Only 5% of conditions affecting women are exclusively gynecological or reproductive in nature.
BIO 2025: Commissioner Martin Makary, M.D., M.P.H., discusses vision for FDA

1 week ago | bio.news | Clary Estes

Food and Drug Administration (FDA) Commissioner Martin A. Makary, M.D., M.P.H., sat down with the Biotechnology Innovation Organization (BIO) President and CEO John F. Crowley to discuss his vision for the FDA. “It’s been exhilarating to meet so many of you,” said Dr. Makary, who assumed his role in March 2025. “And also hear what your ideas are for the FDA.”He discussed topics including communication with sponsors, structural and staffing changes at FDA, and why he’s excited about AI.
BIO 2025: How do we talk about vaccines now?

1 week ago | bio.news | Clary Estes

Public health advocates are reevaluating the vaccine landscape, revisiting long-held assumptions about vaccine policy during both public health emergencies and periods of relative calm. “Obviously, we all, as a globe, lived through one of the most horrible pandemics we’ve seen,” said Phyllis Arthur, MBA, Executive Vice President & Head of Healthcare Policy and Programs at the Biotechnology Innovation Organization (BIO), on June 17 at the BIO International Convention in Boston.
Patient’s mother advocates for newborn screening program reform

3 weeks ago | bio.news | Clary Estes

In April 2025, the Department of Health and Human Services (HHS) announced it would disband the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC). For 15 years, the Advisory Committee has played a key role in determining which conditions should be part of the newborn screening program—a program to detect, diagnose and intervene early in heritable conditions that affect a child’s long-term health or survival.
Arthritis Awareness Month: AiArthritis puts a focus on patients

1 month ago | bio.news | Clary Estes

May is Arthritis Awareness Month, and in observance, Bio.News asked AiArthritis to discuss how it is advancing the needs of patients with autoimmune and autoinflammatory arthritis diseases across the United States. Globally, there are 450 million people living with one of the over 100 diseases classified as autoimmune and autoinflammatory arthritis.
BIO Coffee Chat offers advice on launching a successful patient advocacy organization

1 month ago | bio.news | Clary Estes

Starting and running a patient advocacy organization is a massive undertaking. It often includes fundraising, standing up and operating a board and non-profit structure, educating and connecting patient communities, providing assistance to patients and families, engaging in policy and research, and much more.